PEG-MGF Dosage: The Peptide With Zero Published Studies
Sold as a long-acting version of mechano growth factor, the IGF-1 splice variant skeletal muscle releases after mechanical overload. The underlying biology is real and published: human muscle biopsies show a transient rise in MGF gene expression after resistance exercise. What's never been published, in any species, is a study of the pegylated peptide itself. Every human data point measures the body's own gene expression, not an injected product.
Reviewed by the PepGuard team · Last reviewed Jul 28, 2026
Pegylated synthetic analog of the C-terminal (E-domain) peptide of IGF-1Ec / mechano growth factor · also sold as Pegylated Mechano Growth Factor, PEGylated MGF
Photo: Eduardo Cano Photo Co. / UnsplashOne row is a real biopsy finding. The rest is invented.
Only one of these rows comes from measuring something in a human body. It didn’t involve an injection.
| What's cited | Range |
|---|---|
| Commonly cited vendor dose | ~200 mcg, once daily, on training days |
| Commonly cited cycle length | 4-6 weeks on, followed by a break, per vendor/forum convention |
| Real human data that exists (endogenous, not injected) | Transient rise in the body's own MGF mRNA within hours of resistance exercise, measured by muscle biopsy in young adults; not observed in elderly subjects in the same study |
| Published pharmacokinetic data for the pegylated product itself | None. No study has measured its absorption, half-life, or clearance in any species. |
There is no clinically validated dose for PEG-MGF, and there's no published pharmacokinetic data (absorption, half-life, clearance) for the pegylated conjugate at all, in humans or animals. The mcg-based protocols that circulate are vendor and forum convention with nothing behind them. The one real human dataset that exists measures the body's own, unmodified MGF mRNA rising transiently in muscle tissue after resistance exercise, via biopsy, in young adults; it says nothing about what happens when a synthetic, pegylated version is injected.
Not one paper has ever tested this specific product.
Mechano growth factor is a real, published finding. In 1996, researchers identified that mechanical overload triggers skeletal muscle to express a splice variant of IGF-1, IGF-1Ec in humans, alongside the usual IGF-1Ea. A 2002 study in the Journal of Physiology measured this directly: eight young subjects showed a significant rise in MGF mRNA after high-resistance exercise, while seven elderly subjects showed none, evidence that the response itself changes with age. A 2009 follow-up tracked the same rise over 16 days after muscle-damaging exercise and confirmed, in cell culture, that the synthetic MGF E-domain peptide signals differently from mature IGF-1.
None of that is a study of “PEG-MGF.” Every one of those findings measured the body’s own, unmodified gene product, in muscle tissue, via biopsy, after real exercise. The pegylated, injectable version sold by research-peptide vendors has never been synthesized and characterized in a peer-reviewed paper under any name we could find, not in a cell line, not in an animal, not in a human. There's no published data on how it's absorbed, how long it lasts, or what a given dose does. Every mcg figure attached to it is vendor convention, not measurement.
Borrowed from mechanism and forums, not from a PEG-MGF trial.
| Signal | Frequency | Context |
|---|---|---|
| Injection site reaction (redness, mild pain) | commonly reported | Consistent with subcutaneous injection generally, not specific to PEG-MGF's mechanism; anecdotal, not from a controlled trial. |
| Numbness or tingling in the injected muscle group | occasionally reported | Frequently mentioned in vendor and forum sources; no controlled human study has measured this systematically. |
| Effects on cell proliferation or cancer risk | unknown / not studied | MGF's mechanism promotes muscle progenitor cell proliferation; IGF-axis peptides raise a theoretical proliferative-signaling caution in review literature, but this has not been studied for PEG-MGF specifically. |
| Safety of the pegylated conjugate over any duration | unknown / not studied | No published trial, human or animal, has tested the pegylated product at all, so there's no safety data of any kind to cite, short-term or long-term. |
Not FDA-approved. Nominated for 503A compounding review, but as of the current list, in the category FDA won't even formally evaluate.
"Mechano growth factor (MGF)" appears on the FDA's current 503A bulk drug substances nominated list (updated May 14, 2026), but it sits in Category 3, "Bulk Drug Substances Nominated Without Adequate Support," the category for nominations FDA considers too poorly documented to even move into active evaluation (Category 1) or flag as a specific safety risk (Category 2). That listing is for the underlying substance name; the PEGylated version sold by research-peptide vendors has never been separately reviewed, named, or evaluated by FDA under any category. Separately, MGF is listed under the World Anti-Doping Agency's S2 category (peptide hormones, growth factors, and related substances), prohibited at all times in competitive sport.
Every claim above, traced back.
The founding human biopsy studies of native MGF, FDA’s current 503A nomination list, and WADA’s prohibited list. Click through and check them yourself.
PEG-MGF questions, answered.
No. No study of any kind, human or animal, has tested the pegylated peptide sold as PEG-MGF. What has been published is human biopsy data showing the body's own, unmodified MGF gene expression rising transiently after resistance exercise, which is a different thing entirely from injecting a synthetic pegylated product and measuring what it does.
Not exactly. "MGF" (mechano growth factor) refers to the natural IGF-1Ec splice variant your muscles express after mechanical overload, which has been measured in human biopsy studies. "PEG-MGF" is a synthetic, pegylated version sold by research-peptide vendors, modified for a longer half-life. Pegylation changes a molecule's pharmacokinetics substantially, and no study has characterized how the pegylated version behaves in any living system.
It's not FDA-approved. "Mechano growth factor (MGF)" appears on FDA's current 503A bulk substances nomination list, but in Category 3, meaning FDA considered the nomination too poorly supported to even move into active evaluation. The pegylated version sold as PEG-MGF has never been separately reviewed by FDA under any category. It's also on WADA's prohibited list for competitive sport.
There isn't one. Every mcg-based protocol circulating online is vendor or forum convention, not derived from a study of the injected product. The only human data that exists at all measures endogenous gene expression after exercise, not an administered dose, so there's no dose-response relationship on record to cite.
Keep researching.
This is a preview of the PEG-MGF report.
Create your account to check any peptide against the full research base.